Skip to content

Enliven Therapeutics

US · ELVN #2416 by market cap Listed 1970
46.53 +0.12 +0.26%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    William Blair Maintains Enliven Therapeutics(ELVN.US) With Buy Rating
    Market Newswire · 2026/10/7
  • Rating change
    Mizuho Securities Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $73
    Market Newswire · 2026/8/18
  • Rating change
    H.C. Wainwright Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $64
    Market Newswire · 2026/7/9
  • Rating change
    TD Cowen Maintains Enliven Therapeutics(ELVN.US) With Buy Rating
    Market Newswire · 2026/10/8
  • H.C. Wainwright Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $73
    Market Newswire · 2026/11/13
  • Rating change
    J.P. Morgan Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $75
    Market Newswire · 2026/10/1
  • Rating change
    Morgan Stanley Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $70
    Market Newswire · 2026/10/5
  • Rating change
    William Blair Initiates Enliven Therapeutics(ELVN.US) With Buy Rating
    Market Newswire · 2026/8/18
  • Rating change
    Morgan Stanley Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $70
    Market Newswire · 2026/10/2
  • JonesTrading Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $70
    Market Newswire · 2026/11/7
  • Barclays Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $78
    Market Newswire · 2026/11/5
  • Rating change
    H.C. Wainwright Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $73
    Market Newswire · 2026/10/19
  • Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $82
    Market Newswire · 2026/11/6
  • Rating change
    A Quick Look at Today's Ratings for Enliven Therapeutics(ELVN.US), With a Forecast Between $68 to $82
    Market Newswire · 2026/8/7
  • Rating change
    LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $70
    Market Newswire · 2026/8/8
  • Rating change
    LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $70
    Market Newswire · 2026/8/8
  • Rating change
    Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $80
    Market Newswire · 2026/7/1
  • Rating change
    Goldman Sachs Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $67
    Market Newswire · 2026/7/22
  • Guggenheim Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $78
    Market Newswire · 2026/11/6
  • Rating change
    Barclays Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $78
    Market Newswire · 2026/8/18
  • Barclays Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $78
    Market Newswire · 2026/10/7
  • Rating change
    A Quick Look at Today's Ratings for Enliven Therapeutics(ELVN.US), With a Forecast Between $45 to $80
    Market Newswire · 2026/6/12
  • Rating change
    JonesTrading Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $70
    Market Newswire · 2026/6/29
  • Rating change
    Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $60
    Market Newswire · 2026/6/15
  • Rating change
    Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $82
    Market Newswire · 2026/8/14

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Enliven Therapeutics discussion 0 comments

Add a comment